CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.54% to 1,289.35 Indian rupees Thursday, on what proved to be an all ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.60% to 1,302.05 Indian rupees Monday, on what proved to be an ...

Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.

Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' ...

Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 ...

Dr Reddy’s Laboratories share price declined more than 6% in the morning trades on Friday post Q3 results that were announced after the market hours of Thursday ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.

Dr Reddy's Laboratories shares dropped nearly 7% on Friday after the company reported a slight increase in net profit for the ...

Dr. Reddy's Laboratories shares fell by 6.2% after the company reported a marginal 2% YoY growth in Q3 FY25 net profit to Rs 1,413 crore. Despite robust revenue growth, Jefferies, Nuvama, and DAM ...

Dr Reddy's Laboratories posted a 2% rise in net profit for Q3 2024, reaching Rs 1,413 crore, driven by strong market ...